presentation by Carlo De Giorgi, CEO, Ulia Pharma
Is converting traditional 3D printing technologies to the pharmaceutical world really the solution? The innovative approach of the Ulia Pharma company aims to modify the current pharmaceutical production machinery to bring them closer to the world of 3d drugs.
What drives you?
A future where making custom pills costs the same as mass production
Why should the delegate attend your presentation?
Because the problem of pharmaceutical 3D printing lies in the process, not in the formulations.
What emerging technologies/trends do you see as having the greatest potential in the short and long run?
IoT-smart capsules will allow, together with pharmaceutical 3D printing, the production of the new generation of drugs
What kind of impact do you expect them to have?
Flexible production processes will avoid overdose phenomena; the control of drug-administration through advanced systems will eliminate the problem of pharmaceutical compliance.
What are the barriers that might stand in the way?
Remuneration based on the effects of therapeutic treatment and not on the basis of unit costs must become the norm
We store medicines like cookies hoping to take less every day, but quality is more important than quantity … at least for drugs
Carlo De Giorgi is the CEO of Ulia Pharma. He has a Master’s Degree in Mechanical Engineering at the Politecnico di Milano, Three years of experience in a pharmaceutical automation company, operating since 2019 in the development of pharmaceutical 3d printing technologies. Carlo De Giorgi is the inventor of the patented “flexible coating” technology.
Ulia Pharma S.r.l. is an Italian SME providing new automated machineries for drug manufacturing aiming to tackle these issues.
Ulia Pharma project will introduce a disruptive innovation in drug manufacturing by offering a proprietary technology that allows replacing the daily ingestion of numerous drugs in a single pill, whose assumption will be monitored by reading a unique barcode via smartphone application. The combination of a flexible dosing system, which allows the dosage to be daily adjusted, combined with the verification of the correct intake of the daily pill, makes the pharmacological treatment extremely powerful even in subjects with high risks of compliance failure. By a process-driven approach, unique in the personalised drug market, the Ulia Pharma project arises from the design of the production machinery to define and produce the optimal pharmaceutical form.
Carlo is speaker at the 2021 edition of the conference.